Lovastatin corrects ERK pathway hyperactivation in fragile X syndrome: potential of platelet's signaling cascades as new outcome measures in clinical trials.
Biomarkers
; 21(6): 497-508, 2016 Sep.
Article
in En
| MEDLINE
| ID: mdl-27058300
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Blood Platelets
/
Lovastatin
/
MAP Kinase Signaling System
/
Fragile X Syndrome
/
Anticholesteremic Agents
Limits:
Female
/
Humans
/
Male
Language:
En
Journal:
Biomarkers
Journal subject:
BIOQUIMICA
Year:
2016
Document type:
Article
Affiliation country:
Country of publication: